SHR-A1811 targets HER2 on the cell surface; after internalization it releases a camptothecin payload that inhibits topoisomerase I to cause DNA damage. Topoisomerase I is the intracellular enzymatic target of the payload, not the targeting antigen, so topo I expression alone is not selectively killed.